Research Papers:
Flexible ligated ruthenium(II) self-assemblies sensitizes glioma tumor initiating cells in vitro
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1772 views | HTML 2287 views | ?
Abstract
Palani Elumalai1,5, Neha Kaushik2,3, Dong Hwan Kim1, Hyunuk Kim4, Su Jae Lee3, Eun Ha Choi2, Ki-Whan Chi1 and Nagendra Kumar Kaushik2
1Department of Chemistry, University of Ulsan, Ulsan, Republic of Korea
2Plasma Bioscience Research Center, Department of Electrical and Biological Physics, Kwangwoon University, Seoul, Republic of Korea
3Department of Life Science, Hanyang University, Seoul, Republic of Korea
4Energy Materials and Convergence Research Department, Korea Institute of Energy Research, Daejeon, Republic of Korea
5Department of Chemistry, Texas A&M University at Qatar, Doha, Qatar
Correspondence to:
Nagendra Kumar Kaushik, email: [email protected]
Ki-Whan Chi, email: [email protected]
Keywords: self-assembly, flexible ligand, arene-ruthenium, metallacycle, solid cancer
Received: January 17, 2017 Accepted: June 18, 2017 Published: July 05, 2017
ABSTRACT
The tumorigenic potentials of residual cancer stem-like cells within tumors represent limitations of current cancer therapies. Here, the authors describe the effects of synthesized flexible, ligated, supramolecular self-assembled chair type tetranuclear ruthenium (II) metallacycles (2–5) on glioblastoma and glioma stem like cells. These self-assemblies were observed to be selectively toxic to glioma cells and CD133-positive glioma stem like cells population. Of the self-assembled compounds tested, metallacycle 4 more efficiently induced glioma stem like cells death within a brain cancer cell population and simultaneously inhibited the formation of free-floating gliospheres by reducing the sphere size. Detailed cell death studies revealed that treatment with metallacycle 4 reduced mitochondrial membrane potentials (an indicator of apoptosis) of glioma stem like cells. These results shows the elimination of cancer stem-like cells using an appropriate ligand binding adaptor offers a potential means of developing metal-based compounds for the treatment of chemo-resistant tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19028